Navigation Links
MEI Pharma CEO to Present at Stifel Healthcare Conference
Date:9/5/2013

SAN DIEGO, Sept. 5, 2013 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at the Stifel Healthcare Conference on Wednesday, September 11, 2013 at 11:30 a.m. Eastern time from the Four Seasons Hotel in Boston. A live webcast of the presentation can be accessed at www.meipharma.com/investor. A replay will be available approximately one hour after the presentation.

(Logo:  http://photos.prnewswire.com/prnh/20120628/LA32362LOGO)

About MEI Pharma
MEI Pharma, Inc. (Nasdaq: MEIP) is a San Diego-based oncology company focused on the clinical development of novel therapies for cancer. The Company's lead drug candidate is Pracinostat, a potential best-in-class, oral HDAC inhibitor being developed for advanced hematologic diseases, such as myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Results from a pilot Phase II clinical trial of Pracinostat in combination with Vidaza (azacitidine) in patients with MDS presented at the American Society of Hematology Annual Meeting in December 2012 showed an overall response rate of 89% (eight out of nine). In June 2013, the Company initiated a randomized, placebo-controlled Phase II trial of Pracinostat in combination with Vidaza in patients with previously untreated MDS. In addition, MEI Pharma is developing two drug candidates derived from its isoflavone-based technology platform, ME-143 and ME-344. For more information, go to www.meipharma.com.

Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials and approved by the FDA as being safe and effective for the intended use. Statements included in this press release that are not historical in nature are "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ materially from those contained in the forward-looking statements, which are based on management's current expectations and are subject to a number of risks and uncertainties, including, but not limited to, our failure to successfully commercialize our product candidates; costs and delays in the development and/or FDA approval, or the failure to obtain such approval, of our product candidates; uncertainties or differences in interpretation in clinical trial results; our inability to maintain or enter into, and the risks resulting from our dependence upon, collaboration or contractual arrangements necessary for the development, manufacture, commercialization, marketing, sales and distribution of any products; competitive factors; our inability to protect our patents or proprietary rights and obtain necessary rights to third party patents and intellectual property to operate our business; our inability to operate our business without infringing the patents and proprietary rights of others; general economic conditions; the failure of any products to gain market acceptance; our inability to obtain any additional required financing; technological changes; government regulation; changes in industry practice; and one-time events. We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.


'/>"/>
SOURCE MEI Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. To Present At The Stifel Nicolaus Healthcare Conference
2. Isis Pharmaceuticals to Present at the 2013 Stifel Healthcare Conference
3. Questcor Pharmaceuticals to Participate in Morgan Stanley Global Healthcare Conference
4. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Stifel Nicolaus Healthcare Conference 2013 On September 11, 2013
5. Pharmaceutical and Medical Device Patent Portfolio Acquisition Opportunities from ICAP Patent Brokerage
6. Market Research Reports: Biologics, Biosimilars, Bioseparation Systems for Biopharmaceutical Markets
7. David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
8. Isis Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
9. Synergy Between Food and Pharma Driving South Americas Economy
10. Immune Pharmaceuticals Inc. Presenting At The 15th Annual Rodman & Renshaw Global Investment Conference In New York City September 8-10th, 2013
11. Auxilium Pharmaceuticals, Inc. to Present at the Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices ... ... The full report suite on the ... fluid external drainage systems, intracranial pressure monitoring devices, detachable coils, ...
(Date:11/30/2016)... , Nov. 30, 2016 Varian Medical Systems ... named America,s Most JUST Company in the Healthcare Equipment ... Forbes magazine,s inaugural "JUST 100 List." The rankings ... largest surveys ever conducted on attitudes towards corporate behavior, ... inaugural list ranks U.S companies against their peers within ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... December 02, 2016 , ... ... Dothan-Wiregrass Area in Alabama are expected to attend the UNCF Dothan-Wiregrass Mayor’s Luncheon ... provide scholarship funds for area students and operating support to UNCF-member institutions, including ...
(Date:12/2/2016)... ... 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces the cover ... he was inspired to practice medicine at an early age by his father, who ... making diagnoses and prescribing medicine,” he states. “It is about building relationships with people; ...
(Date:12/2/2016)... ... December 02, 2016 , ... Mediaplanet is ... USA Today, which covers the innovative treatments, therapeutic technologies, and revolutionized nutrition that ... “We are prolonging life 6 years in the last 3 decades,” says Dr. ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today CloudMine, a secure, cloud-based ... named the best Sales Team of 2016 as part of the 2016 SIIA ... the Software & Information Industry Association (SIIA), the principal trade association for the ...
Breaking Medicine News(10 mins):